Chonluten Peptide 20mg

Description

What Is Chonluten Peptide?

Chonluten peptide is a synthetic tripeptide bioregulator with the amino acid sequence Glu-Asp-Gly (EDG), developed by Professor Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology as part of the Khavinson bioregulator peptide program. Chonluten belongs to the class of short regulatory peptides known as bioregulator peptides — low-molecular-weight compounds that exhibit tissue-specific gene expression modulation at physiological concentrations. Chonluten’s target tissue is the bronchopulmonary system, where it has been studied for its capacity to restore normal gene expression patterns in respiratory epithelial cells and bronchial tissue in preclinical and clinical gerontology research models.

Unlike conventional pharmaceutical compounds that act through receptor agonism or enzyme inhibition, Khavinson bioregulator peptides such as chonluten operate through direct interaction with specific DNA sequences in the promoter regions of target genes. This epigenetic mechanism of action — modulating transcription rather than blocking or activating receptors — represents a fundamentally different approach to tissue function restoration that has been the subject of over four decades of research at the St. Petersburg Institute. PrymaLab Chonluten 20mg is manufactured to high purity standards and supplied exclusively for qualified preclinical research applications.

Chonluten 20mg: Key Specifications

How Chonluten Works: Bioregulator Mechanism of Action

Chonluten operates through the Khavinson model of peptide bioregulation, in which short peptides (2–4 amino acids) interact with specific complementary DNA sequences in gene promoter regions, modulating the transcription of genes critical to tissue-specific function. This mechanism was first proposed by Khavinson and Anisimov in the early 2000s and has since been supported by molecular biology studies demonstrating direct peptide-DNA binding in cell-free and in vitro systems.

Epigenetic Gene Expression Modulation

Research published by the St. Petersburg Institute demonstrates that chonluten selectively modulates the expression of genes involved in bronchopulmonary tissue homeostasis. In aged respiratory tissue models, chonluten has been shown to restore gene expression patterns toward profiles characteristic of younger tissue, suggesting a restorative rather than stimulatory mechanism. This epigenetic approach differentiates bioregulator peptides from growth factors or cytokines that directly stimulate cell proliferation, instead acting at the transcriptional regulation level to normalize tissue function.

Respiratory Tissue Specificity

Among the Khavinson bioregulator peptide family, chonluten exhibits preferential activity in bronchial and pulmonary tissue. Preclinical studies have examined chonluten’s effects on bronchial epithelial cell gene expression, mucin production regulation, anti-inflammatory cytokine modulation, and respiratory epithelial barrier integrity. The tissue specificity of short bioregulator peptides is hypothesized to derive from the complementary matching between the peptide’s amino acid sequence and specific DNA motifs enriched in the promoter regions of tissue-specific genes — a selectivity mechanism analogous to transcription factor-DNA recognition but operating through much smaller molecular entities.

Chonluten Peptide Benefits: What Research Shows

The following research context reflects published preclinical and clinical gerontology literature from the Khavinson research program. PrymaLab Chonluten 20mg is supplied exclusively for research purposes and is not intended for therapeutic use.

Bronchopulmonary Function in Aging Models

Chonluten has been studied in gerontological models examining age-related decline in respiratory function. Khavinson’s research group reported that administration of chonluten in aged animal models was associated with normalization of bronchial epithelial cell function, improved mucociliary clearance markers, and restoration of respiratory gene expression profiles toward patterns observed in younger animals. These findings position chonluten within the broader bioregulation hypothesis — that short peptides can restore tissue-specific gene expression patterns that deteriorate during biological aging.

Anti-inflammatory Respiratory Effects

Preclinical studies have examined chonluten’s effects on inflammatory signaling in bronchial tissue models. Research from the St. Petersburg Institute indicates modulation of pro-inflammatory cytokine expression in respiratory epithelial cells, including effects on IL-6 and TNF-α pathways. These anti-inflammatory properties are consistent with the broader bioregulator hypothesis that peptide-mediated gene expression normalization reduces the chronic low-grade inflammation (inflammaging) associated with tissue aging.

Respiratory Epithelial Barrier Integrity

The integrity of the respiratory epithelial barrier is critical to lung defense against pathogens and environmental insults, and declines with biological aging. Chonluten research has examined its effects on tight junction protein expression and epithelial cell differentiation markers in bronchial tissue models, with published data suggesting improved barrier function parameters in aged tissue treated with the peptide.

Chonluten vs. Bronchogen: Respiratory Bioregulator Comparison

PrymaLab offers two Khavinson bioregulator peptides targeting the respiratory system. The following table summarizes the key distinctions for researchers selecting between them.

How to Store and Handle PrymaLab Chonluten 20mg

1. Store lyophilized at −20°C. Keep the sealed vial in a dedicated laboratory freezer, desiccated and protected from light. Lyophilized chonluten peptide is stable for 24+ months under these conditions.
2. Allow vial to reach room temperature before opening. Removing a cold vial and immediately opening it can introduce condensation moisture that degrades the peptide.
3. Reconstitute with appropriate sterile solvent. Use bacteriostatic water, sterile saline, or another solvent appropriate for your research protocol. Add solvent slowly along the vial wall to avoid foaming.
4. Use reconstituted solution within 2–4 weeks. Store reconstituted peptide at 2–8°C. Mark the reconstitution date on the vial label.
5. Avoid repeated freeze-thaw cycles. If the full quantity will not be used in a single session, aliquot the reconstituted solution into single-use portions before freezing.
6. Retain the Certificate of Analysis. Record the lot number and keep the COA for the duration of your research for traceability and data integrity purposes.

Why Choose PrymaLab Chonluten 20mg?

PrymaLab supplies Chonluten 20mg as a high-purity research-grade bioregulator peptide verified by reverse-phase HPLC at ≥98% purity and identity-confirmed by mass spectrometry. Each production batch is assigned a unique lot number and accompanied by a Certificate of Analysis documenting purity, identity, and quality testing results. Testing is conducted by independent analytical laboratories to ensure unbiased results and full traceability. PrymaLab’s commitment to batch-level documentation supports the data integrity requirements of GLP-compliant research environments and peer-reviewed publication standards.

Frequently Asked Questions About Chonluten Peptide

What is chonluten and what class of compounds does it belong to?

Chonluten is a synthetic tripeptide with the sequence Glu-Asp-Gly (EDG) belonging to the Khavinson bioregulator peptide class. Bioregulator peptides are short (2–4 amino acid) compounds developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology that exhibit tissue-specific gene expression modulation. Chonluten’s target tissue is the bronchopulmonary system, and it has been studied in preclinical and gerontological research models for over two decades.

What are the reported chonluten peptide benefits in research?

Published research from the Khavinson program reports that chonluten peptide benefits include normalization of respiratory gene expression patterns in aged tissue models, modulation of inflammatory cytokines in bronchial tissue, improvement of mucociliary clearance markers, and restoration of respiratory epithelial barrier integrity. All reported benefits are from preclinical and gerontological research settings and do not represent therapeutic claims.

How does chonluten differ from bronchogen?

Both chonluten (EDG) and bronchogen (AED) are Khavinson respiratory bioregulator peptides, but they differ in amino acid sequence and research focus. Chonluten has been studied for broader bronchopulmonary gene expression modulation and anti-aging respiratory effects, while bronchogen targets bronchial mucosal repair and has been studied more specifically in chronic bronchitis and COPD research models. Some research protocols use both peptides together for comprehensive respiratory tissue support.

How should chonluten 20mg be stored?

Store lyophilized chonluten at −20°C, desiccated and protected from light, where it is stable for 24+ months. After reconstitution with sterile solvent, store at 2–8°C and use within 2–4 weeks. Avoid repeated freeze-thaw cycles. Aliquot reconstituted solution into single-use portions if the full quantity will not be used in one session.

What purity and testing standards does PrymaLab apply?

PrymaLab Chonluten 20mg is verified at ≥98% purity by reverse-phase HPLC and identity-confirmed by mass spectrometry. Each batch ships with a unique lot number and Certificate of Analysis. All testing is conducted by independent analytical laboratories to ensure unbiased quality verification and full supply chain traceability for research documentation purposes.

Research Disclaimer

For Research Use Only. PrymaLab Chonluten 20mg is intended exclusively for qualified preclinical research use by trained laboratory professionals. This product is not intended for human consumption, therapeutic use, veterinary treatment, or any application outside controlled research environments. Chonluten has not been approved by the FDA or any equivalent regulatory authority for therapeutic use. All research applications described on this page are drawn from published preclinical and gerontological literature. Researchers are solely responsible for ensuring compliance with all applicable institutional and regulatory requirements.